fluorouracil has been researched along with Alzheimer Disease in 3 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Concerned by the devastating effects of Alzheimer's disease, and the lack of effective drugs, we have carried out the design of a series of tacrine-phenolic heterodimers in order to tackle the multifactorial nature of the disease." | 1.51 | Tacrine-O-protected phenolics heterodimers as multitarget-directed ligands against Alzheimer's disease: Selective subnanomolar BuChE inhibitors. ( Bartolini, M; Bolognesi, ML; Fernández-Bolaños, JG; Franconetti, A; Hicke, J; Lagunes, I; López, Ó; Maya, I; Monti, B; Naldi, M; Padrón, JM; Petralla, S; Poeta, E; Roldán-Peña, JM; Romero-Real, V, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Candia, M | 1 |
| Zaetta, G | 1 |
| Denora, N | 1 |
| Tricarico, D | 1 |
| Majellaro, M | 1 |
| Cellamare, S | 1 |
| Altomare, CD | 1 |
| Roldán-Peña, JM | 2 |
| Alejandre-Ramos, D | 1 |
| López, Ó | 2 |
| Maya, I | 2 |
| Lagunes, I | 2 |
| Padrón, JM | 2 |
| Peña-Altamira, LE | 1 |
| Bartolini, M | 2 |
| Monti, B | 2 |
| Bolognesi, ML | 2 |
| Fernández-Bolaños, JG | 2 |
| Romero-Real, V | 1 |
| Hicke, J | 1 |
| Franconetti, A | 1 |
| Petralla, S | 1 |
| Poeta, E | 1 |
| Naldi, M | 1 |
3 other studies available for fluorouracil and Alzheimer Disease
| Article | Year |
|---|---|
New azepino[4,3-b]indole derivatives as nanomolar selective inhibitors of human butyrylcholinesterase showing protective effects against NMDA-induced neurotoxicity.
Topics: Alzheimer Disease; Azepines; Butyrylcholinesterase; Cell Line, Tumor; Cholinesterase Inhibitors; Hum | 2017 |
New tacrine dimers with antioxidant linkers as dual drugs: Anti-Alzheimer's and antiproliferative agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antineoplastic Agents; Anti | 2017 |
Tacrine-O-protected phenolics heterodimers as multitarget-directed ligands against Alzheimer's disease: Selective subnanomolar BuChE inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antineoplastic Agents; Butyrylcholinesterase; Cell | 2019 |